Health and Healthcare

The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers

The bull market is nearing six years old. It turns out that the biotech sector again managed a huge outperforming year in 2014 as well. The gains of the key biotech exchange traded funds (ETFs) were up in the 40% range, with the NYSE Arca Biotech index up over 45% year-to-date. The equal-weight biotech ETF performed better than the key larger ETFs, which signals that the small-cap and mid-cap biotechs were where the big gains were.

Amazingly, some 28 biotech stocks with market capitalization rates north of $300 million were up 100% or more so far in 2014. It was also amazing to see that seven of those 28 stocks were up 300% or more. 24/7 Wall St. wanted to highlight the top seven biotechs of this group, and only one of these top gainers was due to a buyout.

We have included the performance of each biotech, ranked in order by performance year-to-date in 2014. Included was the share price, general trading range, analyst price targets and the driving force behind each of these gains. Again, these are those biotechs screened with $300 million market caps and higher. Additional color has been added if there were recent capital raises.

OvaScience, up 394%

OvaScience Inc. (NASDAQ: OVAS) was trading at $45.56 at Monday’s close, against a 52-week range of $5.51 to $50.44. Its market cap is $1.07 billion, and the consensus analyst price target is at $62.00.

OvaScience spent the first half of 2014 as a stock under $10, and the rally took it up to $30 by the start of December, before it really flew higher. The big driver here is the company’s fertility studies, and OvaTure is said potentially to be the first hormone-free fertility in vitro. In December, OvaScience announced that it had advanced all three fertility treatment options. Revenue is expected to pick up in 2015 to almost $23 million from effectively zero previously, but one analyst sees revenues above $50 million.

Agios, up 378%

Agios Pharmaceuticals Inc. (NASDAQ: AGIO) closed trading Monday at $115.60, and its consensus analyst price target is $102.83. The stock has a 52-week trading range of $21.70 to $124.39. The market cap is $4 billion.

Agios nearly doubled from the start of 2014 through the end of September, but things really launched since then. Agios recently took advantage of its move by raising around $250 million in a stock sale. Its focus is cancer metabolism and genetic disorders, and the company recently reported positive Phase 1 data in healthy volunteers for its AG-348 — what would be a first-in-class investigational medicine to target the underlying cause of pyruvate kinase deficiency.

ALSO READ: Is Gilead Already Coming Back in Favor?

Radius, up 376%

Radius Health Inc. (NASDAQ: RDUS) ended Monday at $39.00. The company had its initial public offering (IPO) in June, and since then has had a range of $7.46 to $42.57. The consensus analyst price target is $45.67, and the market cap is $1.2 billion.

Radius Health is a fresh IPO in 2014, having come public this summer at $8.00 per share. Its stock rose to $25 by December, but it has since risen to nearly challenge $40.00. Jefferies even recently raised its target to $45, and Cantor Fitzgerald doubled its price target to $52. Shortly before Christmas, Radius reported positive top-line Phase 3 results evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis.

Receptos, up 334%

Receptos Inc. (NASDAQ: RCPT) traded at $126.80 as of Monday’s close, nearer the high end of its 52-week trading range of $24.53 to $139.40. The consensus analyst price target is $144.50, and the market cap is $3.4 billion.

Receptos joined the $100+ stock price biotech club in 2014, but the bulk of its move has taken place since the end of October, when shares were under $70. The big driver of late was the company showing promising results for its ulcerative colitis drug, RPC1063. Then in November the company raised some $360 million to fund ongoing studies for that candidate for multiple sclerosis, ulcerative colitis and Crohn’s, as well as to fund other programs.

Bluebird, up 329%

Bluebird Bio Inc. (NASDAQ: BLUE) ended trading at $93.66 on Monday, compared to its consensus analyst price target of $102.80. The stock has a 52-week trading range of $17.40 to $94.49, and the company has a market cap of $2.6 billion.

Shares nearly doubled over the summer, rising from $20 to $40, and then they went parabolic in December when the stock rose from around $40 to $90. The company took advantage of this share strength by raising some $225 million in an equity sale in December. Bluebird’s last big pop was due to positive study results from its hemoglobin drug product.

ALSO READ: Flex Pharma Files for IPO

TG Therapeutics, up 315%

TG Therapeutics Inc. (NASDAQ: TGTX) was trading at $16.01 at Monday’s closing bell, against its 52-week trading range of $3.69 to $18.88. The consensus analyst price target is $23.20, and the market cap is $705 million.

TG Therapeutics had a series of gains, followed by light pullbacks and larger gains, throughout 2014. Amazingly, Roth Capital Partners assigned a new $33 price target in December, so one analyst sees it potentially doubling yet again. Prior to that upgrade, the company announced that its preliminary data from ongoing Phase 1/2 dose escalation study of TG-1101 (Ublituximab) was encouraging in safety and efficacy in combination with TGR-1202 in heavily pre-treated relapsed/refractory B-cell malignancies.

Prosensa, up 303%

Prosensa Holding N.V. (NASDAQ: RNA) traded at $18.75 at the close on Monday, well above its consensus analyst price target of $14.89. The 52-week trading range is $4.12 to $22.80, on a market cap of $677 million.

Prosensa came public in 2013, and 2014 has been a year of recapturing its losses of last year. This gain is tied to a buyout by BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), so no further analysis is needed.

ALSO READ: Analyst Picks Top 5 Pharma Stocks for 2015

Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.